Compound: Brilacidin or Other HDP Mimics Topi
Post# of 72446
Posted On: 09/13/2016 11:08:34 AM
Compound: Brilacidin or Other HDP Mimics
Topical Applications, Otic Infections and Related Formulation Work
The Company has made a significant breakthrough in the formulation of Brilacidin. Previously, Brilacidin could only be stored in a refrigerated state. The Company has now developed a formulation of Brilacidin to be stable at room temperature. However, further formulation work is still needed for each indication. Upon developing optimal formulations, the Company plans to advance these drugs into the clinic.
Cellceutix is conducting preclinical experiments on topical Brilacidin for use in ear-related infections, such as otitis externa or draining otitis media. Studies are now ongoing at a major U.S. university with significant expertise in ototoxic studies. Should these studies be successful, the Company will plan for clinical trials. We believe there is a significant financial opportunity in pursuing this market as there is an unmet medical need for an otic drug to treat MRSA infections. We are less likely to be effected by generic competition due to Brilacidin’s MRSA and anti-inflammatory properties.
Krishna in his most effect environment, the lab.
Topical Applications, Otic Infections and Related Formulation Work
The Company has made a significant breakthrough in the formulation of Brilacidin. Previously, Brilacidin could only be stored in a refrigerated state. The Company has now developed a formulation of Brilacidin to be stable at room temperature. However, further formulation work is still needed for each indication. Upon developing optimal formulations, the Company plans to advance these drugs into the clinic.
Cellceutix is conducting preclinical experiments on topical Brilacidin for use in ear-related infections, such as otitis externa or draining otitis media. Studies are now ongoing at a major U.S. university with significant expertise in ototoxic studies. Should these studies be successful, the Company will plan for clinical trials. We believe there is a significant financial opportunity in pursuing this market as there is an unmet medical need for an otic drug to treat MRSA infections. We are less likely to be effected by generic competition due to Brilacidin’s MRSA and anti-inflammatory properties.
Krishna in his most effect environment, the lab.
(3)
(0)